Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU.

Abstract

In the EU, once-daily memantine 20 mg (Axura(®), Ebixa(®)) is an option for the management of patients with moderate to severe Alzheimer's disease (AD). In pooled clinical trials and studies in the clinical practice setting, memantine 20 mg/day improved cognition, functional ability and behavioural symptoms in this patient population. The beneficial effects… (More)
DOI: 10.1007/s40266-012-0041-0

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.